VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054. Phone: 07405699869, email: info@vivanzabiosciences.com, website: www.vivanzabiosciences.com CIN: L24110GJ1982PLC005057

1st February, 2025

To, Corporate Relationship Department, BSE Limited Ground Floor, P.J.Tower, Dalal Street, Fort, Mumbai- 400001

BSE Script Code: 530057

Subject-Intimation under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

In terms of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of newspaper advertisement published in English daily newspaper (Indian Express) and one daily newspaper (Financial Express) in Gujarati language of the region, where the registered office of the company is situated for extract of Unaudited Financial Results for the Quarter and Nine Months ended on December 31, 2024.

Please take the same on your records.

Thanking you,

Yours Faithfully,

For Vivanza Biosciences Limited

JAYENDRA MEHTA Managing Director DIN: 08210602

Encl: As above

KR®NOX

KRONOX LAB SCIENCES LIMITED

(CIN: U24117GJ2008PLC055460)

Regd. Office: Block No. 353, Village: Ekalbara, Taluka: Padra, District: Vadodara - 391440, Gujarat, India Email: cs@kronoxlabsciences.com Phone No: 02662 - 244077 / 244088

Extract of Statement of Standalone Unaudited Financial Results

	for the Quarter and Nine Months Ended 31-12-2024							
	(Rs. In Lakhs except per share d							
	Particulars	Quarter ended 31.12.2024	Corresponding Quarter ended 31.12.2023	Nine Months ended 31.12.2024				
1	Total Income from Operations	2,483.01	2,072.49	7,567.46				
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items)	882.66	579.84	2,595.75				
3	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary items)	882.66	579.84	2,595.75				
4	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary items)	652.86	473.68	1,915.19				
5	Total Comprehensive Income for the period [comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	657.61	477.53	1,928.13				
6	Equity Share Capital	3,710.40	3,710.40	3,710.40				
7	Earnings per share (of ₹ 10/- each) (for continuing and discontinued operations)							
	Basic & Diluted (Rs.)	1.77	1.29	5.20				

- Notes: 1. The Financial results for the quarter and nine months ended December 31, 2024 have been reviewed by Audit Committee and approved by Board of Directors at its meeting held on January 31, 2025, The Statutory Auditor of the Company have carried out limited review of the above unaudited financial results and have issued an unqualified Limited Review Report.
 - 2. Figures of earlier period have been Regrouped, wherever necessary.
 - The above is an extract of the detailed format of the financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015 The Quarterly financial results in the detailed format are available on the websites of BSE and NSE at www.bseindia.com and www.nseindia.com respectively and on the Company's website at www.kronoxlabsciences.com. The same can be accessed by scanning the QR coded provided below.



For Kronox Lab Sciences Limited Jogindersingh Jaswal Managing Director DIN: 02385809

TENDER NOTICE NO. 29 / 2024 - 25

Date: 31.01.2025

Place: Vadodara

Online tenders for 1 work of Estimated cost of Rs.30.68 Lacs and total cost Rs. 30.68 Lacs, Under different schemes are invited from Regd. Class Contractors by Executive Engineer, Panchayat R & B Dn. Jamnagar. (Ph. No. 2670286). This tenders are available on https://tender.nprocure.com and tenders are to be quoted online from this site. Tender notice is available on Notice board of this office & also on website www.statetenders.gujarat.gov.in online tender submission date are as under. Tenders are not be accepted by post or in person. Further Corrigendum not published in news paper but corrigendum seen only online at website

Doc. Down loading and submission Date & Time	Dt. 04-02-2025 to 11-02-2025 upto 18.00 hours.				
Tender Opening Time & Date	Dt. 12-02-2025 at 12.00 hours.				
NF-695-JAM-2025					



(Regd. Office PSEB Head Office, The Mall, Parials)
Corporate Identification Number (CIN): U40109PB2010SGC033813 Web sliet www.pspcl.in; (Contact Number 9646118754)

Dy.CT/ Hydel Projects, PSPCL, Shed A-3, Shakti Vihar, PSPCL, Patiala invites E-Tender for Design, manufacturing, supply, supervision of nstallation and commissioning of 03 nos Float cum Boost Charger for 02 nos 220V,400AH Battery banks of Shanan Power House, Joginder Nagar, H.P. For detailed NIT & tender specification please refer to https://eproc.punjab.gov.in from 05.02.2025 (11:00 AM) onwards. Corrigendum and Addendum, if any will be published online at

PUNJAB STATE POWER CORPORATION LIMITED

Tender Enquiry No. 331/HPS/ED-US-431 VOL-II Dated:38.01.2025

https://cproc.punjub.gov.in No. 41315 /PB

Rajasthan Knowledge Corporation Limited					
7-A, Jhalana Institutional Area, Behind RTO, Jaipur-302004					
Notice Inviting e-bid/bid					

Date: 31.01.2025 RKCL invites e-bids for following from eligible bidders: -									
S.No.	NIB No.	Subject Matter	SPPP UBN No.						
1 RKCL/ 24-25/816		e bid for Selection of an Agency for e-content development of RKCL Courses Learning modules on Rate-contract basis	KCL2425SLR C00015						

Particulars of bid may be visited on the procurement portal (https://eproc.rajasthan.gov.in, https://sppp.rajasthan.gov.in) of the MD, RKCL

Noida Power Company Limited, Greater Noida Electric Sub Station, Knowledge Park-IV, Greater Noida-201310 (CIN: U31200UP1992PLC014506)

	TENDER NOT	ICE	Date: 01.02.2025						
ealed tender under two Bid System (Commercial & Technical) are invited for following job from all interested bidders									
NIT No.	Tender Description	EMD	Start & Due Date & Time of Submission						
NPCL/FY24-25	Annual RC for Supply of LT Cable (Lot 1.)	2.5 Lacs	01.02.2025 & 24.02.2025						

Cost of Individual Tender Document (Incl. GST) Rs. 1180/-

For other tender details and further amendment/corrigendum, please visit our website www.noidapower.com-->Procurement->Tenders

DGM (CMM)

ONLINE TENDERING

STATUE OF UNITY AREA DEVELOPMENT AND TOURISM GOVERNANCE AUTHORITY TENDER NOTICE NO.18 & 19 YEAR 2024-25

Tender for below mentioned works are invited by Executive Engineer, Division 2, SOU ADTGA, Ekta Naga

from	eligible government registered contractor				
http	//nprocure.com, for more information				
Sr.	Name of Work	Tender Amount (in tecs)	Tender Fees	Earnest Amount Not less than 6 Month	Category
1	Repairing and Maintenance of office & mess erea of CISF Campus at Ekta Negar.	24.77	Rs.1062	Rs 24,000	Class * E1* & above
2	Providing and Fixing Traffic calming instruments and Road marking implementation work for Cycle Track at Ekta Nagar (2 nd attempt)	75.58	Rs.2832	Rs.75,000	Class * D* & above
Onli	ne Submission Last Date			On date 14/02/2025 Up to 18.00 hours.	
	der Fees / Earnest Money and other document subm vsical Submission Last Date)	ission date		Up to date 21 Up to 18.00 ho	
	Physical Submission Last Date) Tender opening Date Price Bid)				2/2025 @ rwards (If

Rajkot Nagarik Sahakari Bank Ltd. (Multistate Scheduled Bank)

For more information visit above website

Possession Notice (For Immovable Property)

http://nprocure.com,

IMF-MARMADA-426-2024-25

R.O. & H.O.: "Arvindbhai Maniar Nagarik Sevalay", 150' Ring Road, Nr. Raiya Circle, Rajkot. Ph. 2555716 Whereas, The undersigned being the authorized officer of Rajkot Nagarik Sahakari Bank Ltd., H.O. Rajkot under the Securitization and Reconstruction of Financial Assets and Enforcement of Security interest Act 2002 Section 13(2) and in exercise of powers conferred under the Security Interest (Enforcement) Rules 2002 Issued a demand notice dated 28/08/2018 by Regd.A.D. Post and public notice on 28/11/2018 in Daily Newspaper "GUJARAT MIRROR" and "AKILA" calling upon the borrower Tamta Kammansingh Nayansingh to repay the amount mentioned in the notice being Rs.10,37,962.00 (Rupees Ten Lacs Thirty Seven Thousand Nine Hundred Sixty Two Only) within 60 days from the date of receipt of the said notice, and interest thereon due from 01/08/2018 within 60 days from the date of receipt of the said notice. The borrowers having failed to repay the amount, notice is hereby given to the borrowers, guaranters and the public in general that the undersigned has taken possession of Properties described herein below through Mamfatdar & Executive Magistrate Morbi City on Dt.28/01/2025 in pursuance of the Order Dt.30/10/2021 issued by the Hon. Dist. Magistrate Morbi City under section 14 of the SARFAESi Act-2002. The borrowe in particular and the public in general is hereby cautioned not to deaf with the following property and any dealing with this property will be subject to the charge of Rajkot Nagarik Sahakari Bank Ltd., Rajkot to an amount outstanding as on 31/12/2024, Rs.23,07,519=00 (Rupees Twenty Three Lacs Seven Thousand Five Hundread Nineteen Only) + interest thereon due from 01/01/2025. The borrower's attention is invited to provisions of sub-section (8) of section 13 of the act, in respect of time available, to redeem the secured

Description of Property

Immovable Property situated in Morbi Dist. (Erstwhile Rajkot), Sub Dist. Morbi, Madhapar gaam Survey No 20 Paiki N.A. Land for Residential Purpose Approx A. 4-09 Guntha Known as Maruti Park Plots Paiki Plot No 3 and 10 Palki Open Land Approx 279-54 Sq Mts Area Palki Making Total 9 Blocks Palki Northward Side Block No 4(Plot No 3 Paiki) Land Approx 31-82 Sq Mts(Approx 342-00 Sq Feet) Ground Floor and First Floor Making Total Built up Area Approx 60-79 Sq Mts alongwith Construction thereon acquired Vide Regd. Sale deed No. 1536 Dated 30/01/2018 in the Name of Shri Tamta Kammansing Nayansing and bounded by as

North :- Adjoining Block No 3 South :- Adjoining Block No 5 East :- Land of Adjoining Plot No.4 West :- N.A. Land Palki Fload

Property Address: Maruti Park, Block No.4, B/h Gayatri Nagar Society, At. Madhapar, Ta.Morbi (Gujarat) Dt. 30/01/2025 Authorized Officer Raikot Nagarik Sahakari Bank Ltd., H.O., Recovery Dept., Rajkot. Rajkot.

Place: Ahmedabad

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054. Phone: 079-26870952, email: info@vivanzabiosciences.com, web:www.vivanzabiosciences.com CIN: L24110GJ1982PLC005057

EXTRACT OF UNAUDITED CONSOLIDATED FINACIAL RESULTS FOR

	THE QUARTER AND NINE MONTHS ENDED ON 31 DECEMBER, 2024										
	(Rs.In lacs except per share date										
SR.			Quarter End	ed	Nine Mo	nth Ended	Year Ended				
NO.	Particulars	31/12/2024 Unaudited	30/09/2024 Unaudited	31/12/2023 Unaudited	31/12/2024 Unaudited	31/12/2023 Unaudited	31/03/2024 (Audited)				
1.	Total Income From Operations	151.08	300.25	657.93	695.58	2349.58	2788.91				
2.	Net Profit for the period (before Tax, Exceptional and/or Extraordinary item)	4.34	1.55	20.60	32.37	96.13	69.52				
3.	Net Profit for the period before Tax (after Exceptional and/or Extraordinary item)	4.34	1.55	20.60	32.37	96.13	69.52				
4.	Net Profit for the period after Tax (after Exceptional and/or Extraordinary item)	4.34	1.55	20.60	32.37	96.13	54.63				
5.	Total Comprehensive income for the period [Comprising profit for the period (after tax) and other comprehensive Income (after tax)	4.34	1.55	20.60	32.37	96.13	54.63				
6.	Equity Share Capital	400	400	400	400	400	400				
7.	Earnings Per Share (of Rs.1/-each) (for continuing and discontinuing operations)										
1.	Basic	0.01	0.00	0.05	0.08	0.24	0.14				
2.	Diluted	0.01	0.00	0.05	0.08	0.24	0.14				

Notes

SR

2.

NO.

The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on January 31, 2025. 2 Information on Standa

nformation on Standalone Financial Results are as follows: (Rs.In lacs except per share data)							
		Quarter Ende	ed	Nine Mo	Year Ended		
Particulars	31/12/2024 Unaudited	30/09/2024 Unaudited	31/12/2023 Unaudited	31/12/2024 Unaudited	31/12/2023 Unaudited	31/03/2024 (Audited)	
Total Income (continuing operation)	77.23	158.52	338.35	278.86	1219.80	1446.73	
Profit / (Loss) before tax from continuing operation	3.86	0.53	18.23	26.90	69.55	42.89	
Profit / (Loss) after tax from continuing operation	3.86	0.53	18.23	26.90	69.55	31.74	
Profit / (Loss) before tax from discontinued operation	0.00	0.00	0.00	0.00	0.00	0.00	

0.00

0.00

The above is an extract of the detailed format of the Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange (www.bseindia.com) and on the Company's website (www.vivanzabiosicences.com)

0.00

Place: Ahmedabad Date: January 31, 2025

Profit / (Loss) after tax from

discontinued operation

Scan the QR Code to view the Unaudited Reults



SD/-For, Vivanza Biosciences Limited Jayendra Mehta Managing Director DIN: 08210602

0.00

0.00

BAHADUR CHAND INVESTMENTS PRIVATE LIMITED

pred office: The Grand Plaza, Plot No.2, Nelson Mandela Road, Vasant Kunj- Phase-II, New Delhi-Correspondence Address: 37, Community Center, Basant Lok, Vasant Vihar, New Delhi – 110057 Fax: 011-26152453, Tel. No: 011 – 47619310, Website: www.bahadurchandinvestments.com

FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024

0.00

	(All amount in Rupees lakhs, unless otherwise stated)										
Standalone Standalone											
S.	Particulars Particulars		Quarter ended		Nine mon	Year Ended					
No.	ratticulais	December 31, 2024	September 30, 2024	December 31, 2023	December 31, 2024	December 31, 2023	March 31, 2024				
		Unaudited	UnaudIted	Unaudited	Unaudited	Unaudited	Audited				
1.	Total Income from Operations	51.77	18,776.49	293.32	18,645.05	16,698.10	65,759.73				
2.	Net Profit/ (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	(9,471.67)	9,022.58	(10,476.90)	(10,032.99)	(11,904.13)	25,590.74				
3.	Net Profit/ (Loss) for the period before tax (after Exceptional and/ or Extraordinary items #)	(9,471.67)	9,022.58	(10,476.90)	(10,032.99)	(11,904.13)	25,590.74				
4.	Net Profit/ (Loss) for the period after tax (after Exceptional and/ or Extraordinary items#)	(9,512.16)	5,193.28	(10,664.70)	(14,016.16)	(15,539.83)	10,336.35				
5.	Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(9,512.16)	5,193.28	(10,664.70)	(14,016.16)	(15,539.83)	10,336.35				
6.	Paid up Equity Share Capital	17.06	17.06	17.06	17.06	17.06	17.06				
7.	Other equity (excluding Revaluation Reserve)	2,99,556.41	3,09,068.57	2,87,696.39	2,99,556.41	2,87,696.39	3,13,572.58				
8.	Securities Premium Account	1,33,995.94	1,33,995.94	1,33,995.94	1,33,995.94	1,33,995.94	1,33,995.94				
9.	Net worth	2,99,573.47	3,09,085.63	2,87,713.45	2,99,573.47	2,87,713.45	3,13,589.64				
10.	Paid up Debt Capital/ Outstanding Debt	7,13,893.55	7,11,189.62	7,52,429.70	7,13,893.55	7,52,429.70	7,67,953.69				
11.	Outstanding Redeemable Preference Shares	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable				
12.	Debt Equity Ratio	2.33	2.26	2.56	2.33	2.56	2.42				
13.	Earnings Per Share (of Rs. 100 /- each) (for continuing and discontinued operations)										
	Basic (in Rs.)	(55,750.56)	30,437.73	(62,505.59)	(82,148.39)	(91,078.62)	60,581.12				
	Diluted (in Rs.)	(55,750.56)	30,437.73	(62,505.59)	(82,148.39)	(91,078.62)	60,581.12				
14.	Capital Redemption Reserve	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable				
15.	Debenture Redemption Reserve	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable				
16.	Debt Service Coverage Ratio	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable				
17.	Interest Service Coverage Ratio	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable				

The above is an extract of detailed format of the Unaudited Standalone financial results for the quarter and nine months ended on December 31, 2024 filed with the Stock Exchange under Regulation 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. The full format of the financial results are available on the websites of the stock exchange at www.nseindia.com and the Company at www.bahadurchandinvestments.com The same can be accessed by scanning the QR code provided below.

The above results for the quarter and nine months ended on December 31, 2024 have been reviewed by the Audit Committee and approved by Board of Directors at its meeting held on January 31, 2025

The above results for the quarter and nine months ended on December 31, 2024 have been reviewed by the Acualt Committee and approved by Board of Directors at its meeting field on January 31, 2025. The financial results of the Company have been prepared in accordance with Indian Accounting Standards (India AS) notified under the Companies (Indian Ascounting Standards) Rules, 2016, prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder and the other accounting principles generally accepted in India. Any application guidance/ directions issued by the Reserve Bank of India or other regulators are implemented as and when they are issued applicable. For the other items referred in Regulation 52 (4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, pertinent disclosures have been made to the Stock Exchange and can be accessed at www.nseindia.com and at the Company's website at www.bahadurchandInvestments.com and can be accessed by scanning the QR code provided below.



For and on behalf of the Board of Directors of Bahadur Chand Investments Private Limite

DIN: 00002803



VADILAL INDUSTRIES LIMITED

Regd. Office: Vadilal House, Shrimali Society, Nr. Navarangpura Railway Crossing, Navrangpura, Ahmedabad - 380 009. Ph.: 079-26407201-09 Fax: 079-30153102 Web: www.vadilalgroup.com,CIN: L91110GJ1982PLC005169, ${\bf Email: shareslogs@vadilal group.com}$

EXTRACT OF STANDALONE & CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND **NINE MONTHS ENDED ON 31st DECEMBER, 2024**

(Rs. In crore except per share data)

		Standalon	Consolidated				
Particulars	Three months ended on 31-12-2024	Nine Months ended 31-12-2024	Corresponding ended on 31-12-2023 in the previous year	Three months ended on 31-12-2024	Nine Months ended 31-12-2024	Corresponding ended on 31-12-2023 in the previous year	
Total income from operations	150.22	793.18	132.92	208.34	977.66	178.10	
Net Profit for the Period before tax, Exceptional Items/ Extraordinary Items	10.15	127.26	(5.97)	17.41	172.39	2.98	
Net Profit for the period before tax	10.15	127.26	(5.97)	17.41	172.39	2.98	
Net Profit for the period after tax	7.47	94.82	(4.47)	11.93	128.33	9.24	
Total Comprehensive Income for the Period	7.49	94.73	(4.62)	15.95	132.53	8.81	
Equity Share Capital	7.19	7.19	7.19	7.19	7.19	7.19	
Earnings Per Share (of Rs. 10 each)							
Basic & Diluted:	10.39	131.92	(6.22)	16.60	178.54	12.86	

- 1. The above is an extract of the detailed format of Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months period ended on 31-12-2024 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015. The full format of the Unaudited Financial Results as on 31-12-2024 are available on Website of BSE, NSE as well as Company's website viz www.vadilalgroup.com and can be accessed by scanning the QR Code mentioned below.
- 2. The above Financial results have been recommended by the Audit Committee and subsequently approved by the Board of Directors at the Board Meeting held on 31st January, 2025 and Limited Review of the above results have been carried out by statutory auditor of the company.





FOR VADILAL INDUSTRIES LIMITED RAJESH R. GANDHI MANAGING DIRECTOR



જુ**ના સ્મોલ ફાયનાન્સ બેંક** (શિડ્યુલ્ક કોમર્સિયલ બેંક) ²જીસ્ટ<u>ર્ક ઓફીસ</u>: ધ ફેરવે, ગ્રાઉન્ડ અને પહેલો માળ, સર્વે નં.૧૦/૧, ૧૧/૨ અને ૧૨/૨ળી, ઓફ ડોમલુર, કોરમંગલા ઇન્ડ ર્સંગ રોડ, ઇજીએલ બિઝનેશ પાર્ક પછી, ચલાઘઢ્ઢા, બેંગ્લોર–પદ્૦૦૭૧.

ખાનગી સંદ્યી મારફત વેચાણની નોટીસ

સિક્યોરીટાઇઝેશન અને રીકન્સ્ટ્રક્શન ઓફ ફાયનાન્સીયલ એસેટ્સ અને એન્ફોર્સમેન્ટ ઓફ સિક્યોરીટી

ઇન્ટરેસ્ટ એક્ટ, ૨૦૦૨ (સરફૈસી એક્ટ) હેઠળ બેંકને ચાર્જડ કારચેલ સ્થાવર મિલકતોનું વેચાણ **જના સ્મોલ ફાયનાન્સ બેંક લીમીટેડ**ના નીચે સહી કરનાર અધિકૃત એધિકોરીએ સરફૈસી એક્ટ હેઠળ નીચે જણાવેલ મિલકતનો **ભૌતિક કબજે** લઇ લીધો છે.

મેસર્સ જના રમોલ ફાયનાન્સ બેંક લીમીટેડના અધિકૃત અધિકારીએ મિલકતોના વેચાણ માટે ઘણી જાહેર હરાજીઓ અગાઉ ચોજી હતી, પરંતુ તે કોઇ બીડ ન મળતા અસફળ રહી હતી. પરિણામે જાણ કરવામાં આવે છે કે જે ઉપર જણાવેલ લોન એકાઉન્ટની કુલ બાકી રકમ આ નોટીસ પ્રસિદ્ધ થયાની તારીખથી **પંદર (૧૫) દિવસ**ની અંદર ચુકવવામાં નહી આવે તો, અધિકૃત અધિકારી નીચે જણાવ્યા મુજબ ખાનગી સંધિ દ્વારા વેચાણની પ્રક્રિયા કરશે.

જાહેર જ્^નતાને જાણ કરવામાં આવે છે કે શીડ્યુલમાં જણાવેલ સિક્ચોર્ડ મિલકત, "જ્યાં છે", "જે છે" ના ધોરણે બેંકના બાકી લેણાની વસુલાત માટે બેંકને માન્ય શરતો મુજબ ખાનગી સંધિ મારફત વેચાણ માટે ઉપલબ્ધ છે.

ખાનગી સં<u>ધિ મારફત મિલકતોના વેચાણની માન્ય શરતો અને નિયમો નીચે મુજબ છે:</u>

૧. ખાનગી સંધિ મારફત વેચાણ, "જ્યાં છે" અને "જે છે" ના ધોરણે રહેશે

૨. ખરીદારે આ નોટીસના પ્રકાશનની સમાપ્તિ પછી વેચાણ કિંમતની ૧૦ ટકા ૨કમ જમા કરવી જરૂરી છે.

3. બેંક દ્વારા ખરીદીની ઓફરની અસ્વીકૃતિના કિસ્સામાં, અરજી સાથે ચુકવેલ કોઈપણ રકમ જણાવેલ સમયગાળા દરમિયાન કોઈપણ વ્યાજ વગર પરત કરવામાં આવશે.

૪. ખરીદાર તેના સંતોષ માટે મિલકત (ખાનગી સંધિ મારફત વેચારા હેઠળ) ને સંબંધિત તમામ પાંસાઓની ચોગ્ય ચકાસણી કરી લેવી જોઇએ. ખરીદાર ત્યારબાદ આ સંબંધમાં અધિકૃત અધિકારી/સિક્યોર્ડ લેણદાર સામે કોઇપણ દાવો કરવા હકદાર ગણાશે નહી.

૫. બેંક કોઇપણ કારણ જણાવ્યા વગર ખરીદીની કોઇપણ ઓકર રદ કરવાનો અનામત હક ધરાવે છે.

૬. ખરીદારે મિલકતની ખરીદીના સંબંધમાં તમામ સ્ટેમ્પ ડ્યુડી, રજાસ્ટ્રેશન ફી અને અન્ય ખર્ચ, વેરા, ડ્યુટીઝ, સોસાયટીની બાકી રકમ વગેરે ભોગવવાના રહેશે. **૭.** વેચાણ સરફૈસી એક્ટ/નિયમોની જોગવાઇઓ અનુસાર રહેશે. <u>શિડ્ચુલ</u>

중મ ન.	ા. લાન અસાઉન્ટ નબર દવાદાર/સહ–દવાદારનું નામ		સરફૈસી એક્ટ હેઠળ ૧૩(૨) માંગણા નોટીસ મુજબની સ્કમ	ખાનગી સંધિ માટે રીઝર્વ કિંમત			
٩			રૂ. ૧૧,૫૪,૨૨૯.૭૦ (રૂપિયા અગિયાર લાખ સોપ્પન હજાર બસ્સો ઓગણત્રીસ અને સીતેર પૈસા પુરા) ૦૮/૧૧/૨૦૨૩ મુજબ	રૂા. ૯,૦૦,૦૦૦/– (રૂપિચા નવ લાખ પુરા)			
	સિ <mark>ક્ચોર્ડ એસેટ્સની વિગત</mark> : બ્લોક/સર્વે નં. ૧૬૩૪ પૈકી પ્રમુખ વિલા કોમ્પેલસ, બ્લોક–એ, અને શોપ નં. ૪ (ગ્રાઉન્ડ ફ્લો૨), જી.પી. નં. ૧૦૧૨૧૫૫/૧૧/૧૪ ક્ષેત્રફળ આશરે ૧૮.૬૦૫ ચો.મી., ગામ બાચડ, તાલુકો બાચડ, જિલો અરવલી ખાતેની બિન–ખેતીલાચક જમીન પર બંધાચેલ એન.એ. કોર્મસીચલ મિલકત.						

સિક્ચોર્ડ મિલકતોના વેચાણ પહેલા ઉપર જણાવેલ બાકી રકમ તેમજ બેંક દ્વારા કરાચેલ તમામ કોસ્ટ, ચાર્જિસ અને ખર્ચ જમા કરીને અહીં ઉપર જણાવેલ સિક્ચોર્ડ મિલકતો છોડાવવા માટે સરફૈસી એક્ટની કલમ ૧૩(૮) ની જોગવાઇઓ પ્રત્યે ઉપરોક્ત દેવાદારો/સહ–દેવાદારોનું ધ્યાન દોરવામાં આવે છે. પત્રવ્યવહારનું સરનામું: શ્રી ચશસ્કર શર્મા (મોબાઇલ નં. ૯૮૯૮૩૩૫૦૦૩), ઇમેઇલ: yashaskar.sharma29@janabank.com અને રંજન નાઇક (મો. નં. ૯૫૯૦૮૫૮૨૪૯), ઇમેઇલ

ranjan.naik@janabank.com જના સ્મોલ ફોચનાન્સ બેંક લીમીટેડ (અગાઉ મેસર્સ જનલક્ષ્મી ફાચનાન્સિયલ સર્વિસિઝ પ્રાઇવેટ લીમીટેડ તરીકે જાણીતી), ઓફીસઃ ગ્રાઉન્ડ ફ્લીર, બીજો માળ, સાંગરીલા આર્કેડ, સારસ્વત બેંક ઉપર, ૧૦૦ ફુટ આનંદ નગર રોડ, શ્ચામલ, અમદાવાદ, ગુજરાત-૩૮૦૦૧૫

તારીખ : ૦૧.૦૨.૨૦૨૫, સ્થળ : ગુજરાત

સહી/– અદ્યિકૃત અધિકારી, જના સ્મોલ ફાયનાન્સ બેંક લીમીટેડ

VIVANZA BIOSCIENCES LIMITED

Regd, Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054. Phone: 079-26870952, email: info@vivanzabiosciences.com, web:www.vivanzabiosciences.com CIN: L24110GJ1982PLC005057

EXTRACT OF UNAUDITED CONSOLIDATED FINACIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31 DECEMBER, 2024

					(F	s.in lacs excep	ot per share data	
SR.	PS-1916 300	3	Quarter Ended			Nine Month Ended		
NO.	Particulars	31/12/2024 Unaudited	30/09/2024 Unaudited	31/12/2023 Unaudited	31/12/2024 Unaudited	31/12/2023 Unaudited	31/03/2024 (Audited)	
1.	Total Income From Operations	151.08	300.25	657.93	695.58	2349.58	2788.91	
2.	Net Profit for the period (before Tax, Exceptional and/or Extraordinary item)	4,34	1,55	20.60	32.37	96,13	69,52	
3.	Net Profit for the period before Tax (after Exceptional and/or Extraordinary item)	4.34	1.55	20.60	32.37	96.13	69.52	
4.	Net Profit for the period after Tax (after Exceptional and/or Extraordinary item)	4.34	1.55	20.60	32.37	96.13	54.63	
5,	Total Comprehensive income for the period [Comprising profit for the period (after tax) and other comprehensive Income (after tax)	4.34	1.55	20.60	32.37	96.13	54,63	
6.	Equity Share Capital	400	400	400	400	400	400	
7.	Earnings Per Share (of Rs.1/-each) (for continuing and discontinuing operations)							
1.	Basic	0.01	0.00	0.05	80.0	0.24	0.14	
2.	Diluted	0.01	0.00	0.05	80.0	0.24	0.14	

The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on January 31, 2025

2. Information on Standalone Financial Results are as follows (Rs.In lacs except per share data) SR Quarter Ended Nine Month Ended Year Ended **Particulars** 30/09/2024 31/12/2023 31/12/2024 31/12/2024 31/12/2023 31/03/2024 Unaudited Unaudited Unaudited Unaudited (Audited) 278.86 1219.80 1446.73 Total Income (continuing operation) 77.23 158.52 338.35 Profit / (Loss) before tax from 3.86 0.53 18.23 26.90 69.55 42.89 Profit / (Loss) after tax from 3.86 0.53 18.23 26.90 69.55 31.74 continuing operation Profit / (Loss) before tax from 0.00 0.00 0.00 0.00 0.00 0.00 discontinued operation Profit / (Loss) after tax from 0.00 0.00 0.00 0.00 0.00 discontinued operation

The above is an extract of the detailed format of the Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange (www.bseindia.com) and on the Company's website

Place: Ahmedabad Date: January 31, 2025

nded ("SEBI ICDR Regulation

Scan the QR Code to view the Unaudited Reults



SD/-For, Vivanza Biosciences Limited Jayendra Mehta Managing Director DIN: 08210602

This is a public announcement for information purposes only and is not a prospectus announcement and does not constitute an invitation or offer to acquire, purchase or subscribe to securities Not for release, publication or distribution directly or indirectly, outside India. Initial public offer of Equity Shares (as defined below) on the main board of BSE Limited ("BSE") and National Stoci Exchange of India Limited ("NSE", and together with BSE, the "Stock Exchanges") in compliance with Chapter II of the Securities and Exchange Board of India (Issue of Capital and Disclosur



DR. AGARWAL'S HEALTH **CARE LIMITED**



Our Company was incorporated as 'Dr. Agarwal's Health Care Limited' at Chennai, Tamil Nadu as a public limited company under the Companies Act, 1956, pursuant to a certificate o incorporation dated April 19, 2010, issued by the Registrar of Companies, Tamil Nadu and Andaman and Nicobar Island at Chennai ("RoC") and commenced operations pursuant to a certificate for commencement of business dated May 29, 2010 issued by the RoC. For details in relation to changes in the registered office of our Company, see "History and Certain Corporate Matters" on page 250 of the Red Herring Prospectus dated January 23, 2025 filed with the ROC ("RHP" or the "Red Herring Prospectus").

Registered Office: 1st Floor, Buhari Towers, No.4 Moores Road, Off Greams Road, Near Asan Memorial School, Chennai 600 006, Tamil Nadu, India Corporate Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai 600 006, Tamil Nadu, India; Telephone: +91 44 4378 7777; Website: www.dragarwals.co.in: Contact person: Thanikainathan Arumugam. Company Secretary and Compliance Officer: E-mail: secretarial@dragarwal.com Corporate Identity Number: U85100TN2010PLC075403

HE PROMOTERS OF OUR COMPANY: DR. AMAR AGARWAL, DR. ATHIYA AGARWAL, DR. ADIL AGARWAL, DR. ANOSH AGARWAL, DR. ASHVIN AGARWAL, DR. ASHAR AGARWAL, DR. AMAR AGARWAL FAMILY TRUST, DR. ADIL AGARWAL FAMILY TRUST, DR. ANOSH AGARWAL FAMILY TRUST, DR. ASHVIN AGARWAL FAMILY TRUST, DR. ASHVIN AGARWAL FAMILY TRUST, AND DR. ASHAR AGARWAL FAMILY TRUST, DR. AGARWAL'S EYE INSTITUTE AND DR. AGARWAL'S EYE INSTITUTE PRIVATE LIMITED

INITIAL PUBLIC OFFER OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹1 EACH ("EQUITY SHARES") OF DR. AGARWAL'S HEALTH CARE LIMITED ("COMPANY") FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹[●] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹[● MILLION COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹1 AGGREGATING UP TO ₹3,000 MILLION BY OUR COMPANY ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 67.842,284 EQUITY SHARES OF FACE VALUE OF ₹1 AGGREGATING UP TO ₹[●] MILLION ("OFFERED SHARES") BY THE SELLING SHAREHOLDERS, CONSISTING OF UP TO 2,176,239 EQUITY SHARES OF FACE VALUE OF ₹1 AGGREGATING UP TO ₹[•] MILLION BY DR. AMAR AGARWAL, UP TO 2,629,829 EQUITY SHARES OF FACE VALUE OF ₹1 AGGREGATING UP TO ₹[●] MILLION BY DR. ATHIYA AGARWAL, UP TO 3,071,188 EQUITY SHARES OF FACE VALUE OF ₹1 AGGREGATING UP TO ₹[●] MILLION BY DR. ADIL AGARWAL, UP TO 3,614,508 EQUITY SHARES OF FACE VALUE OF ₹1 AGGREGATING UP TO ₹[●] MILLION BY DR. ANOSH AGARWAL, UP TO 241,269 EQUITY SHARES OF FACE VALUE OF ₹1 AGGREGATING UP TO ₹[●] MILLION BY DR. ASHVIN AGARWAL, UP TO 1,883,869 EQUITY SHARES OF FACE VALUE OF ₹1 AGGREGATING UP TO ₹[●] MILLION BY DR. AGARWAL'S EYE INSTITUTE (COLLECTIVELY "THE PROMOTER SELLING SHAREHOLDERS"), UP TO 7,083,010 EQUITY SHARES OF FACE VALUE OF ₹1 AGGREGATING UP TO ₹[●] MILLION BY ARVON INVESTMENTS PTE. LTD., UP TO 16,148,150 EQUITY SHARES OF FACE VALUE OF ₹1 AGGREGATING UP TO ₹[●] MILLION BY CLAYMORE INVESTMENTS (MAURITIUS) PTE. LTD., AND UP TO 30,755,592 EQUITY SHARES OF FACE VALUE OF ₹1 AGGREGATING UP TO ₹[●] MILLION BY HYPERION INVESTMENTS PTE. LTD. (COLLECTIVELY THE "INVESTOR SELLING SHAREHOLDERS"), UP TO 119,315 EQUITY SHARES OF FACE VALUE OF ₹1 AGGREGATING UP TO ₹[●] MILLION BY FARAH AGARWAL, UP TO 119,315 EQUITY SHARES OF FACE VALUE OF ₹1 AGGREGATING UP TO ₹[●] MILLION BY URMILA AGARWAL (COLLECTIVELY THE "OTHER SELLING SHAREHOLDERS") (THE PROMOTER SELLING SHAREHOLDERS, THE OTHER SELLING SHAREHOLDERS AND THE INVESTOR SELLING SHAREHOLDERS, COLLECTIVELY REFERRED TO AS THE "SELLING SHAREHOLDERS") AND SUCH EQUITY SHARES OFFERED BY THE SELLING SHAREHOLDERS ("OFFER FOR SALE", AND TOGETHER WITH THE FRESH ISSUE, THE "OFFER")

THE OFFER INCLUDES A RESERVATION OF UP TO 1,579,399 EQUITY SHARES OF FACE VALUE OF ₹1, AGGREGATING UP TO ₹[●] MILLION (CONSTITUTING UP TO [●]% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL), FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES ("EMPLOYEE RESERVATION PORTION") AND A RESERVATION OF UP TO 1,129,574 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION (CONSTITUTING UP TO [●]% OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL) FOR SUBSCRIPTION BY ELIGIBLE AEHL SHAREHOLDERS ("SHAREHOLDER RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION AND THE SHAREHOLDER RESERVATION IS HEREINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER SHALL CONSTITUTE [●] % AND [●] % OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. RESPECTIVELY.

CORRIGENDUM: NOTICE TO INVESTORS

Please note that in the issue closing advertisement published in The Economic Times, Mint, Hindu Business Line, Financial Express, Jansatta, Business Standard and Mumbai Samachar, "Bid/ Offer Opens Today" was inadvertently mentioned instead of "Bid/ Offer Closes Today"

Please note that the Bid/Offer opened on Wednesday, January 29, 2025 and the Bid/Offer closes on Friday, January 31, 2025.

All capitalised terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP

For DR. AGARWAL'S HEALTH CARE LIMITED

Place: Chennal

Thanikainathan Arumugam

Company Secretary & Compliance Office DR. AGARWAL'S HEALTH CARE LIMITED is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offer of its Equity Shares and has filed the RHP with the RoC. The RHP is made available on the website of the SEBI at www.sebi.gov.in as well as on the websites of the BRLMs i.e., Kotak Mahindra Capital Company Limited at https://investmentbank.kotak.com, Morgan Stanley India Company Private Limited at www.morganstanley.com/india, Jefferies India Private Limited at www.jefferies.com and Motilal Oswal Investment Advisors Limited at www.motilaloswalgroup.com, the website of the NSE at www.nseindia.com and the website of the BSE at www.bseindia.com and the website of the Company at www.dragarwals.co.in. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risks, please see the section titled "Risk Factors" beginning on page 33 of the RHP. Potential investors should not rely on the DRHP filed with

SEBI for making any investment decision and instead should place reliance on the RHP. This announcement does not constitute an invitation or offer of securities for sale in any jurisdiction. The Equity Shares have not been and will not be registered under the U.S. Securities Act or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (i) within the United States solely to persons who are reasonably believed to be "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) pursuant to Section 4(a) of the Securities Act, or (ii) outside the United States in "offshore transactions" as defined in and in compliance with Regulation S under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occur. There will be no public offering of the Equity Shares in the United States

Dhani Services Limited (CIN: L74110HR1995PLC121209)

Extract of Unaudited Consolidated Financial Results for the quarter and nine months ended 31 December 2024

(₹ in Crores)

Sr. No.	Particulars	Quarter ended	Nine months ended	Quarter ended	Year ended
		31.12.24 (Unaudited)	31.12.24 (Unaudited)	31.12.23 (Unaudited)	31.03.24 (Audited)
1.	Total income from operations (net)	94.91	304.92	87.11	422.85
2.	Net Profit/(loss) for the period (before Tax, Exceptional and/or Extraordinary items)	30.83	(26.78)	(87.12)	(334.50)
3.	Net Profit/(loss) for the period before tax (after Exceptional and/or Extraordinary items)	30.83	(26.78)	(87.12)	(334.50)
4.	Net Profit/(loss) for the period after tax (after Exceptional and/or Extraordinary items)	5.22	(73.94)	(89.46)	(373.94)
5.	Total comprehensive income for the period	0.80	(745.71)	(85.88)	(367.58)
6.	Paid-up equity share capital (Face Value of ₹ 2/- per Equity Share)	121.64	121.64	121.64	121.64
7.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	3,323.63
8.	Earnings per Share (EPS) (Face Value of ₹ 2/- per Equity Share) *(EPS for the quarters and nine months not annualised)				
	-Basic (Amount in ₹) -Diluted (Amount in ₹)	0.08 * 0.08 *	(1.07)* (1.07)*	(1.55)* (1.55)*	(6.49) (6.49)

1. The above results have been reviewed by the audit committee and subsequently approved at the meeting of the Board of Directors held on 31 January 2025.

2. Key Standalone Financial Information:

(₹ in Crores)

	(/ 1110						
_	Particulars	Quarter ended	Nine months ended	Quarter ended	Year ended		
Sr. No.		31.12.24 (Unaudited)	31.12.24 (Unaudited)	31.12.23 (Unaudited)	31.03.24 (Audited)		
1.	Total income from operations (net)	5.34	19.65	27.70	92.74		
2.	Net Profit/(loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(10.97)	(33.99)	7.32	27.25		
3.	Net Profit/(loss) for the period before tax (after Exceptional and/or Extraordinary items)	(10.97)	(33.99)	(15.35)	4.58		
4.	Net Profit/(loss) for the period after tax (after Exceptional and/or Extraordinary items)	(8.06)	(33.38)	(20.18)	(14.38)		
5.	Total comprehensive income for the period	(8.06)	(33.46)	(20.18)	(14.30)		
6.	Paid-up equity share capital (Face Value of ₹ 2/- per Equity Share)	121.64	121.64	121.64	121.64		
7.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	5633.59		
8.	Earnings per Share (EPS) (Face Value of ₹ 2/- per Equity Share) *(EPS for the quarters and nine months not annualised)						
	-Basic (Amount in ₹) -Diluted (Amount in ₹)	(0.14)* (0.14)*	(0.58)* (0.58)*	(0.35)* (0.35)*	(0.25) (0.25)		

Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Company's website (http://www.dhani.com) and on the website of BSE (http://www.bseindia.com) and NSE (http://www.nseindia.com). The same can be accessed by scanning the QR code provided below.



Udvog Vihar, Phase 1, Gurgaon-122016. Corporate Identification Number: L74110HR1995PLC121209

Registered Office: 5th Floor, Plot No. 108, IT Park,

For and on behalf of the Board of Directors Divyesh B. Shah Whole-time Director & CEO

Date: 31 January 2025

Bharti AXA Life Insurance Company Ltd. IRDAI Regd. No. 130 dated 14/07/2006 | CIN No.: U66010MH2005PLC157108 | Website: www.bhartiaxa.com Registered Office: Unit No. 1902, 19th Floor, Parinee Crescenzo, 'G' Block, Bandra Kurla Complex, BKC Road, Behind MCA Ground, Bandra East, Mumbai

Trade Logos Librari and AN used in the document belong to the Bharti Enterprises (Holdings) Private Ltd. and AXA SA respectively and are used by Bharti AXA Life under license See Regulation 47 (1) (b) of the SEBI (LODR) Regulations, 2015 read with IRDAI Circular Reference IRDA/F&I/REG/CIR/208/10/2016 dated 25th October, 2016.

SI. No.	Particulars	For the Period ended December 31, 2024	For the Period ended December 31, 2023	For the Year ended March 31, 2024
1.	Premium Income (Gross) (Refer note (c))	1,89,430	1,90,621	2,90,830
2.	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(6,086)	(14,623)	(14,589
3.	Net Profit/(Loss) for the period before tax (after Exception and/or Extraordinary items) (Refer note (d))	(6,086)	(14,623)	(14,589
4.	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	(6,086)	(14,623)	(14,589
5.	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)] (Refer note (e))	-	-	
6.	Equity Share Capital	3,92,820	3,84,120	3,84,12
7.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year (Refer note (f))	20,744	20,744	20,74
8.	Earnings Per Share (of Rs.10/- each) :-			
	1. Basic:	(0.16)	-0.38	-0.38
	2. Diluted:	(0.16)	-0.38	-0.3

This format is modified to reflect the terminology used in the Insurance Act and IRDAI Regulations.
The above is an extract of the detailed format of Quarterly/Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015.
Premium income is gross of reinsurance and net of Goods and service tax.
Net Profit (Loss) before tax, for the period would be Profit before tax as appearing in Profit and Loss Account (Shareholders' account).
Line item no. 5 needs to be disclosed when Ind-AS becomes applicable to the Company.
Reserves shown excluding Revaluation reserve and fair value change account.
There are no exceptional and /or extraordinary items adjusted in the Statement of Policyholders' and Shareholders' account in accordance with AS Rules.





